Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

被引：0
|
作者：
Demosthenes Makris
Arnaud Scherpereel
Marie Christine Copin
Guillaume Colin
Luc Brun
Jean Jacques Lafitte
Charles Hugo Marquette
机构：
[1] CHRU of Lille,Pulmonary and Thoracic Oncology Department
[2] INSERM Unit 774,Pathology Department
[3] Institut Pasteur of Lille,Clinique des Maladies Respiratoires
[4] CHRU of Lille,undefined
[5] Hôpital Albert Calmette,undefined
[6] CHRU de Lille,undefined
来源：
BMC Cancer | / 7卷
关键词：
Docetaxel; Gemcitabine; Human Epidermal Growth Factor Receptor; Erlotinib; Interstitial Lung Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Recurrent Erlotinib-Induced Interstitial Lung Disease on Non-Small Cell Lung Cancer
    Park, Sang Don
    Kim, Areum
    Park, Jin-Seok
    Shin, Chun Ho
    Nam, Hae Sung
    Kim, Lucia
    Cho, Jae Wha
    Ryu, Jeong Sun
    Kwak, Seung Min
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2009, 67 (05) : 445 - 448
  • [22] Fatal Interstitial Lung Disease after Addition of Sorafenib to a Patient with Lung Adenocarcinoma Who Had Failed to Improve with Erlotinib Alone
    Guan, Yin
    Meng, Jing
    Zhao, Hong
    Hu, Yi
    Yan, Xiang
    Zhao, Shao-Hong
    Jiao, Shun-Chang
    CASE REPORTS IN ONCOLOGY, 2014, 7 (01): : 273 - 276
  • [23] Lung transplantation: a therapy for interstitial lung disease?
    Whelan, Timothy P. M.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2006, 11 (05) : 502 - 507
  • [24] Cancer therapy-related interstitial lung disease
    Zhou Chengzhi
    Deng Haiyi
    Yang Yilin
    Wang Fei
    Lin Xinqing
    Liu Ming
    Xie Xiaohong
    Luan Tao
    Zhong Nanshan
    中华医学杂志英文版, 2025, 138 (03)
  • [25] Cancer therapy-related interstitial lung disease
    Zhou, Chengzhi
    Deng, Haiyi
    Yang, Yilin
    Wang, Fei
    Lin, Xinqing
    Liu, Ming
    Xie, Xiaohong
    Luan, Tao
    Zhong, Nanshan
    CHINESE MEDICAL JOURNAL, 2025, 138 (03) : 264 - 277
  • [26] Interstitial lung diseases associated with lung cancer
    Herranz, Laura Sierra
    Garcia, Javier Juan
    Alcazar, Jesus Villegas
    Gonzalez, Elizabeth De Freitas
    Garcia, Silvia Garcia
    Lopez, Piedad Rivas
    de Miguel, Elena Bollo
    Ortega, Inmaculada Herraez
    Orcajo, Nieves Alonso
    Fernandez, Florentino Diez
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [27] Independent review of fatal interstitial lung disease (ILD) in TRIBUTE:: paclitaxel plus carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC).
    Gandara, D. R.
    Yoneda, K.
    Shelton, D.
    Beckett, L. A.
    Ramies, D. A.
    Bloss, J.
    Herbst, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 381S - 381S
  • [28] Successful Erlotinib Rechallenge After Erlotinib-Induced Interstitial Lung Disease
    Dallas, Jennifer L.
    Jantz, Michael A.
    Lightsey, Judith L.
    Sonntag, Christopher
    Kaye, Frederic J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 1142 - 1143
  • [29] Successful retreatment with erlotinib after erlotinib-related interstitial lung disease
    Turk, Haci M.
    Adli, Mustafa
    Simsek, Melih
    Aliyev, Altay
    Besiroglu, Mehmet
    TUMORI JOURNAL, 2021, 107 (06): : NP84 - NP86
  • [30] Interstitial Lung Disease Associated with Lung Cancer: A Case-Control Study
    Gibiot, Quentin
    Monnet, Isabelle
    Levy, Pierre
    Brun, Anne-Laure
    Antoine, Martine
    Chouaid, Christos
    Cadranel, Jacques
    Naccache, Jean-Marc
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (03)
12345